-
Article
Open AccessSurvival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study
Most gastrointestinal stromal tumors (GISTs) harbor c-KIT or PDGFRA mutations. Administration of tyrosine kinase inhibitors (TKIs) has significantly improved the survival of patients with GISTs. We aimed to evalu...
-
Article
Open AccessAdjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
Adjuvant FOLFOX (5-fluorouracil and oxaliplatin) chemotherapy benefits stage III colon cancer patients. However, it still results in side effects and increased cost. Reducing cycles had been thought to decreas...
-
Article
Open AccessCancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy
The impact of KRAS signaling on cancerous inhibitor of protein phosphatase 2A (CIP2A) expression has not yet been explored. We investigated the impact of KRAS on CIP2A expression in colorectal cancer patients ...
-
Article
Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study
We aimed to compare the treatment efficacy of cetuximab versus bevacizumab in combination with either irinotecan-based or oxaliplatin-based regimens (targeted triplet) as the first-line treatment for patients...
-
Article
TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma
The molecular and genetic changes underlying esophageal squamous cell carcinoma (ESCC) tumor formation and rapid progression are poorly understood. Using high-throughput data analysis, we examined molecular ch...
-
Article
Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism
A dozen clinical trials examining a combination of temsirolimus and cetuximab in treating metastatic colon cancer are currently underway. We investigated the role of cancerous inhibitor of protein phosphatase ...
-
Article
Concurrent Chemoradiotherapy Followed by Metastasectomy Converts to Survival Benefit in Stage IV Rectum Cancer
To investigate the impact of concurrent chemoradiotherapy (CCRT) on stage IV rectum cancer.
-
Article
Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study
This open-label pilot study is aimed to evaluate the efficacy and tolerability of the antidepressant duloxetine, which is effective for diabetic neuropathic pain, in the treatment of chronic oxaliplatin-induce...
-
Article
CIP2A Is a Predictor of Poor Prognosis in Colon Cancer
The cancerous inhibitor of protein phosphatase 2A (CIP2A) oncoprotein is overexpressed in colon cancer tissue compared to normal colon mucosa. We investigated the impact of CIP2A on colon cancer.
-
Article
Open AccessEvaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study
Carcinoma of unknown primary site (CUP) has a poor prognosis and the prognostic factors in these patients are not well established. Furthermore, there are no selection criteria for patients who should benefit ...
-
Article
Liver Abscess After Liver Metastasectomy is a Poor Prognostic Factor in Patients with Colorectal Cancer
More and more complications of extensive hepatic resection are being encountered in patients treated for liver metastases from colorectal cancer. This study aimed to determine the impact of liver abscess after...
-
Article
Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin’s lymphoma: the single-institute experience in Taiwan
Primary pulmonary lymphoma (PPL) accounts for less than 1% of patients with non-Hodgkin’s lymphoma, with no report in Chinese patients. This study aims to analyze the clinical features and prognosis of this po...
-
Article
High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma
Several reports recently found that patients with B cell non-Hodgkin’s lymphoma (NHL) had a higher carrier rate of hepatitis B surface antigen (HBsAg). The current study aimed to examine the hepatitis B virus ...
-
Article
Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation
The use of monoclonal antibody, rituximab, had been reported to be associated with some severe viral infections. The inference of rituximab therapy and post-transplant cytomegalovirus (CMV) infectious complica...
-
Article
Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP
Although adding rituximab to standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is an efficacious and well-tolerated regimen in elderly patients with diffuse large B cell l...
-
Article
Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication
The most well-known adverse events of oxaliplatin are hematologic toxicity, gastrointestinal tract toxicity, and sensory neuropathy. However, hypersensitivity reaction of oxaliplatin, especially severe anaphyl...
-
Article
N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data
Although adding oxaliplatin to fluorouracil and leucovorin in adjuvant chemotherapy for colon cancer may improve disease-free survival, grade 3–4 sensory neuropathy also increases. To determine whether oral N-ace...
-
Article
Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer
The response to chemotherapy of solid tumors is generally assessed by measuring tumors visualized by imaging. However, the response assessment based on imaging is not always feasible because patients often hav...
